IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 8, April 2023

Review on Study of A Novel Insulin Delivery Method for the Treatment of Diabetes

Yash Hadge[1], Nilesh Gorad[2], Rohit Auti[3], Dipak Solanke[4], Saurabh Sivse[5]
Department of Pharmacology
Samarth College of Pharmacy, Bangarwadi, Belhe, Pune, Maharashtra, India
yashhadge2001@gmail.com

Abstract: *Diabetes consequences include both microvascular and macrovascular disease, which are both influenced by proper diabetes management. Because insulin injection therapy is difficult for many patients, novel methods of insulin delivery are of interest in the diabetes profession. This examination will discuss pulmonary insulin administration by inhalation. Since the 1920s, Lispro insulin has been used to treat diabetes mellitus nevertheless, regardless ofa variety of formulations, exhaustive insulin treatment accompanying many regular injections has not been acquired by universal clinical approval. Inhaled insulin, on the other hand, appears to be adirect, well-indulged, non-invasive alternative to subcutaneous routine insulin. Moreover, inhaled insulin has a more physiological insulin description than traditional insulin. Further studies are wanted to validate general efficacy and pulmonary security, to equate the various approaches, and to typify better their relative places in essence. As a result of the acknowledgment of the significance of closer control of glycemia and the increasing number of cases with type 2 diabetes the one enduring insulin, inhaled insulin keep senhancinga progressively integral indiscriminate nudging diabetes..*

Keywords: Diabetes Type 1, medication formulations, Drug delivery methods, insulin, portal system, nanoparticles, biodegradable polymers.

REFERENCES

[1]. Essential of Medical Pharmacology , Jaypee Production, K.D. Tripathi , Volume 8th edition (2013), 276-294.
[2]. Overview of novel routes of Insulin : Current Status, Lopamudra roy, International Journal of Advances in Medicine · October 2020.
[3]. Diabetes fact sheet no.312 : World Health Organization ;2013 ,
[4]. Karounos DG, Bryson JS, Cohen DA. Metabolically inactive insulin analog prevents type 1 diabetes in prediabetic NOD mice. J Clin Invest. 1997;100:1344-1348.
[5]. Fry A. Insulin delivery device technology 2012: where are we after 90 years ? J Diabetes sci Techno 2012;6;947-53.
[6]. Journal of emerging technologies and innovative research (JETIR) , Novel routes of insulin for diabetes treatment, S.G. Nagargoje , A.A. Muchandi.
[7]. Skyler J. Pulmonary inhaled insulin: an overview and prediction for the future. Symposium: Alternate routes of insulin administration. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement 2.
[8]. Ricordi C. Lilly Lecture: Islet transplantation: a brave new world. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association; June 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement 2.
[9]. Karounos D. Immune response to insulin: Implications for alternative route insulin therapy. Symposium: Alternate routes of insulin administration. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association; September 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement 2.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 8, April 2023

[10]. Karounos DG, Bryson JS, Cohen DA. Metabolically inactive insulin analog prevents type 1 diabetes in prediabetic NOD mice. J Clin Invest. 1997;100:1344-1348.

[11]. Diabetes Prevention Trial -- Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685-1691.

[12]. Smaldone GC. Concepts of aerosol therapy for the modern clinician. Symposium: Alternate routes of insulin administration. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement 2.

[13]. Skyler J. Pulmonary inhaled insulin: an overview and prediction for the future. Symposium: Alternate routes of insulin administration. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement 2.

[14]. Kapitza C, Hompesch M, Thompsen LK, Heise T. Intra-subject variability of pulmonary insulin via the AERx insulin diabetes management system versus subcutaneous insulin. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Poster 417-P. Diabetes, Volume 51, Supplement 2.

[15]. Rosenstock J, for the Exubera Phase III Study Group. Mealtime rapid-acting inhaled insulin (Exubera) improves glycemic control in patients with type 2 diabetes failing combination oral agents: 3 month, randomized, comparative trial. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Poster 535-P. Diabetes, Volume 51, Supplement 2.

[16]. Modi P, Yutzy P, Klein K, Levin P. Oral insulin increases post-prandial insulin peaks and improves glucose control in type 2 diabetic patients. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Poster 440-P. Diabetes, Volume 51, Supplement 2.

[17]. Smith AM, Woods TJ, Williams DJ, et al. Transdermal basal insulin delivery through microspheres. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Abstract 191-OR. Diabetes, Volume 51, Supplement 2.

[18]. Saudek CD. Update on implantable pumps. In: Symposium: Alternate routes of insulin administration. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. September 14-18, 2002; San Francisco, California. Diabetes, Volume 51, Supplement

[19]. Saudek CD, Selam JL, Pitt HA, et al. A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med. 1989;321:574-579.

[20]. Walter H. Insulin delivery by implanted pumps: one-year trial with programmable infusion systems (the Point Study). Int J Artif Organs. 1989;12:793-798.

[21]. Dunn FL, Nathan DM, Scavini M, Selam JL, Wingrove TG. Long-term therapy of IDDM with an implantable insulin pump. The Implantable Insulin Pump Trial Study Group. Diabetes Care. 1997;20:59-63.

[22]. Hanaire-Broutin H, Broussolle C, Jeandidier N, et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Evaluation dans le Diabete du Traitement par Implants Actifs. Diabetes Care. 1995;18:388-392.

[23]. Saudek CD, Duckworth WC, Giobbie-Hurder A, et al. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. JAMA. 1996;276:1322-1327.

[24]. L Heinemann. "Overcoming obstacles: new management options", European Journal of Endocrinology, 2004

[25]. Elena Matteucci, Ottavio Giampietro, Vera Covolan, Daniela Giustarini, Paolo Fanti, Ranieri Rossi. "Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) <1% delivery", Drug Design, Development and Therapy, 2015

[26]. Eman Mahmoud Shaaban, Doha Elsayed Ellakwa, Nesma Mohamed Elaraby, Khalda Sayed Amr, Ahmed Mahmoud Mohamadin. "The effect of insulin-loaded gold and carboxymethyl chitosan nanoparticles on gene expression of glucokinase and pyruvate kinase in rats with diabetes type 1", Journal of Food Biochemistry, 2022

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 8, April 2023

[27]. https://www.pharmatutor.org/articles/recent-trends-in-insulin-drug-delivery-system
[28]. https://www.medscape.org/viewarticle/438371
[29]. https://healthhearty.com/pathophysiology-of-diabetes-mellitus#:~:text=The%20pathophysiology%20of%20Type%201%20diabetes%20mellitus%20suggests,Consequently%2C%20the%20pancreas%20secretes%20little%20or%20no%20insulin
[30]. https://www.endo.theclinic.com/article/S08898529(13)00037-6.
[31]. https://pdfcookie.com/
[32]. https://www.ijmedicine.com/index.php/ijam
[33]. https://diabetestalk.net/